New perspectives
for brain therapeutics

New research to investigate role of blood-brain barrier in neurological conditions

A new consortium of 27 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases.

Project kick-off meeting at Sanofi with the consortium members.

The blood-brain barrier (BBB) is a protective layer between the brain’s blood vessels and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing through into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies.On the other hand, several neurological diseases could originate from a dysfunctional blood brain barrier.

On the other hand, several neurological diseases could originate from a dysfunctional blood brain barrier.


The project is coordinated by the Nuffield Department of Clinical Neurosciences (NDCN) at the University of Oxford. The Oxford team’s principal investigator and IM2PACT project coordinator, Zameel Cader, said: “With this funding, we will be able to develop more sophisticated models that replicate the human blood-brain barrier far more accurately, allowing us to investigate how the barrier acts at a molecular level during disease.”
Dominique Lesuisse, Head of the Central Nervous System Barrier Group at Sanofi and IM2PACT project advisor, added: “Our existing models are not effective enough at telling us which drugs in particular biotherapeutics will break through the blood-brain barrier. IM2PACT will progress the state of the art and help devise optimal ways of getting therapies into the brain.”


The funding from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders by:
  • discovering and developing innovative and effective brain transport mechanisms
  • establishing and characterising BBB models with good predictability in health and disease
  • identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered BBB under disease conditions
  • in-depth understanding of the biology of the BBB and characterisation of various pathophysiological mechanisms across the BBB

IM2PACT will foster the development of disease-modifying treatment in a setting of personalised medicine.

With a budget of €18m, €9m of direct funding from IMI and €9m of in-kind funding from industry, IM2PACT is forming a large partnership to better understand the blood-brain barrier. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest public private partnership and is funded jointly by the European Union´s Horizon 2020 research and innovation programme and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).


Project Facts

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 807015. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

international partners
months interval
Proudly powered by Wpopal.com